PCSK9|https://phgkb.cdc.gov/GAPPKB/phgHome.do|Updates on Specific Diseases

https://phgkb.cdc.gov/GAPPKB/phgHome.do




Last Posted: May 29, 2017

---

• Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol.  
  Slomski Anita et al. JAMA 2017 May (20) 2054
• How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?  
  Masana Luis et al. Atherosclerosis 2017 May 262107-112
• National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session  
  National Lipid Association, May 2017
• NLA Expert Panel on Treatment with PCSK9 Inhibitors: 2017 recommendations[PDF 84.3 KB]  
  National Lipid Association, May 2017
• PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations.  
  Waters David D et al. Circulation research 2017 May 120(10) 1537-1539
• PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.  
  Schmidt Amand F et al. The Cochrane database of systematic reviews 2017 Apr 4CD011748
• Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association  
  CE Orringer et al, J Clin Lipidology, May 2017
• NLA Expert Panel on Treatment with PCSK9 Inhibitors: 2017 recommendations  
  National Lipid Association, May 2017
• New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.  
  Ellis Katrina L et al. European journal of preventive cardiology 2017 Jan 2047487317708890
• Nine paths to PCSK9 inhibition  
  A Mullard, Nature Rev Drug Discovery, April 2017
• Genetic Architecture of Familial Hypercholesterolaemia.  
  Sharifi Mahtab et al. Current cardiology reports 2017 May 19(5) 44
• PCSK9 Inhibition to Reduce Cardiovascular Events.  
  Dullaart Robin P F et al. The New England journal of medicine 2017 Mar
• PCSK9 Inhibition to Reduce Cardiovascular Events  
  Robin P.F. Dullaart, NEJM, March 17, 2017
• Analysis of Children and Adolescents with Familial Hypercholesterolemia.  
  Minicocci Ilenia et al. The Journal of pediatrics 2017 Feb
• Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.  
  Glueck Charles J et al. Lipids in health and disease 2016 Mar 1555
• Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.  
  Arca Marcello et al. Atherosclerosis 2016 Sep

more